Likewise, in patient #34, the discontinuation sample at +169 days showed the presence of one CTC that did not contain that tumor’s dominant PIK3CA mutation, but instead harbored a hotspot IDH1 mutation (Fig. 2, #34, Discontinuation, CTC#: E6). This evidence concerns the gene IDH1 and neoplasm.